Lineage Cell Therapeutics Inc (AMEX:LCTX) price on current trading day, rose 7.38% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.41.
A look at the stock’s price movement, the close in the last trading session was $0.39, moving within a range at $0.3655 and $0.4166. The beta value (5-Year monthly) was 1.327. Turning to its 52-week performance, $1.47 and $0.38 were the 52-week high and 52-week low respectively. Overall, LCTX moved -22.20% over the past month.
Lineage Cell Therapeutics Inc’s market cap currently stands at around $94.68 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-09.
The average forecast suggests up to a 19.11% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 11.28M, representing a 18.72% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that LCTX is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
LCTX’s current price about -11.91% and -26.18% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 36.58, while 7-day volatility ratio is 9.02% and 8.27% in the 30-day chart. Further, Lineage Cell Therapeutics Inc (LCTX) has a beta value of 1.41, and an average true range (ATR) of 0.04.
If we refocus on Lineage Cell Therapeutics Inc (AMEX:LCTX), historical trading data shows that trading volumes averaged 1.57 over the past 10 days and 1.56 million over the past 3 months. The company’s latest data on shares outstanding shows there are 228.36 million shares.
The 0.44% of Lineage Cell Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 51.14% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 22.34 million on 2025-03-14, giving us a short ratio of 18.33. The data shows that as of 2025-03-14 short interest in Lineage Cell Therapeutics Inc (LCTX) stood at 1550.9999999999998 of shares outstanding, with shares short rising to 21.55 million registered in 2025-02-14. Current price change has pushed the stock -17.49% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the LCTX stock continues to rise going into the next quarter.
